Display options
Cite
Pantuck AJ, Zismon A, Tso CL, et al. Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate Cancer Prostatic Dis. 2000;3(4):280-282doi: 10.1038/sj.pcan.4500473.
Pantuck, A. J., Zismon, A., Tso, C. L., & Belldegrun, A. S. (2000). Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate cancer and prostatic diseases, 3(4), 280-282. https://doi.org/10.1038/sj.pcan.4500473
Pantuck, A J, et al. "Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model." Prostate cancer and prostatic diseases vol. 3,4 (2000): 280-282. doi: https://doi.org/10.1038/sj.pcan.4500473
Pantuck AJ, Zismon A, Tso CL, Belldegrun AS. Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate Cancer Prostatic Dis. 2000 Dec;3(4):280-282. doi: 10.1038/sj.pcan.4500473. PMID: 12497078.
Copy Download .nbib Format: NLM
Share it on

Prostate Cancer Prostatic Dis. 2000 Dec;3(4):280-282. doi: 10.1038/sj.pcan.4500473.

Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model.

Prostate cancer and prostatic diseases

A J Pantuck, A Zismon, C-L Tso, A S Belldegrun

Affiliations

  1. Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA, USA.

PMID: 12497078 DOI: 10.1038/sj.pcan.4500473

Abstract

In most clinical trials of intermittent androgen deprivation (IAD), the decision to stop androgen withdrawal is based on monitoring PSA levels, waiting for its drop to nadir. Based on in vitro pre-clinical studies, a modified 'on-off' schedule of short intervals of androgen deprivation, designated pulsed androgen deprivation (PAD), is proposed to destroy androgen dependent (AD) cells more gradually and to conserve their androgen-independent (AI) inhibitory potential for longer periods, resulting in an overall prolongation of time to hormone resistant progression.Prostate Cancer and Prostatic Diseases (2000) 3, 280-282

Publication Types